Research & development
Liquid medicine innovation
We invest heavily in research, development, and technological advancements. This means that we can create new, effective solutions for patients, as well as assess the latest progression in the field.
Rosemont aims to develop liquid medication formulations that patients find effective and palatable. These should feature minimal excipients, making many of them suitable for patients of all ages, with a variety of religious and dietary requirements.
We listen to our customers and respond to their needs through a continual programme of new product development. Our approach is to always avoid excipients of concern wherever possible, to ensure that our liquid medications are suitable for the widest range of patient groups.
All our products comply with EU safe excipient level guidelines, reassuring our patients and healthcare professionals of their quality. Our products are also developed in accordance with the European Commission and Evaluations of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) safety guidelines.
Take a look at our video which highlights Rosemont Pharmaceuticals’ investment in a new Innovation Centre.
Rosemont are committed to the pursuit of excellence in everything that we do, always striving to uphold the highest quality standards. We adhere to Good Manufacturing Practice (GMP) and International Conference on Harmonisation (ICH) Q10 quality control guidelines.
Our manufacturing facilities are also regularly inspected by both the UK and US pharmaceutical regulatory agencies. Additional inspections come from the many healthcare institutions, customers and companies purchasing Rosemont liquid medicines worldwide.
Alongside this, Rosemont has invested a seven-figure sum into a new Innovation Centre development. The aim of the facility is to increase liquid medicine output, develop new products suitable for multiple markets, and enhance company growth.
The pharmaceutical company’s scientific team is continually developing new effective solutions for patients. We also research the latest advancements in the field, including partnering with leading companies on modified-release liquid medications.